Tonix Pharmaceuticals Reveals Promising Preclinical Data for Cancer Immunotherapy TNX-1700
Tonix Pharmaceuticals presented positive preclinical results for TNX-1700, a fusion protein showing potential in reducing immunosuppressive cells and enhancing anti-tumor immune responses in gastric cancer models, particularly when combined with anti-PD1 therapy.
Tonix Pharmaceuticals has shared promising preclinical data for its immuno-oncology candidate TNX-1700 at the American Association for Cancer Research (AACR) 2025 Annual Meeting. The research revealed significant potential in addressing challenges within the tumor microenvironment, specifically in gastric cancer treatment.
The study demonstrated that a fusion protein version of TFF2 could substantially reduce immunosuppressive neutrophils, a critical factor in cancer progression. Researchers noted enhanced anti-tumor immune responses, particularly when the treatment was combined with anti-PD1 therapy, suggesting a potential breakthrough in cancer immunotherapy.
This development is significant because it addresses a key limitation in current cancer treatments: the ability to overcome immunosuppressive mechanisms within tumors. By targeting neutrophils and improving immune response, TNX-1700 could potentially offer a more effective approach to treating gastric and colon cancers.
The research is part of Tonix's strategic collaboration with Columbia University, focusing on developing innovative treatments that can modulate the tumor microenvironment. While preclinical data is preliminary, it represents an important step in potentially creating more robust cancer therapies that could improve patient outcomes.